Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms, Unknown Primary × alectinib × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 12 Neoplasms 4 Lung Neoplasms 4 Solid Tumors 1 Neoplasms, Unknown Primary 1 Neoplasms by Site 1 Neoplasms by Histologic Type 1 Neoplasm Metastasis 1 Multiple Endocrine Neoplasia Type 2a 1 Lymphoproliferative Disorders 1 Lymphoma, Large-Cell, Anaplastic 1 Lung Diseases 1 Hematologic Neoplasms 1 Genomic Instability 1 Central Nervous System Neoplasms 1 Carcinoma, Hepatocellular 1 Brain Neoplasms 1 Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer 1 ALK+ Advanced NSCLC 1

Interventions

pembrolizumab 2 atezolizumab 2 zenocutuzumab 1 sintilimab 1 pertuzumab 1 pemigatinib 1 olaparib 1 ivosidenib 1 ipatasertib 1 entrectinib 1 cobimetinib 1 alectinib 1 Whole Genome Sequencing 1 Vemurafenib 1 Transurethral Resection of Prostate 1 Specimen Handling 1 Sequence Analysis, RNA 1 Radiosurgery 1 Paclitaxel 1 Magnetic Resonance Spectroscopy 1 HhAntag691 1 Genetic Testing 1 Genetic Profile 1 Gemcitabine 1 Fluorodeoxyglucose F18 1 FAPI-46 1 Erlotinib Hydrochloride 1 Cisplatin 1 Carboplatin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03498521 2025-11-19

CUPISCO

Hoffmann-La Roche

Phase 2 Completed

529 enrolled 16 charts

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡